Pharmacologic treatment of gastroparesis: What is (still) on the horizon?

D Schweckendiek, D Pohl

Journal: Current opinion in pharmacology 2023;72():102395

PMID: 37639905

Free Full Text on Elsevier Science View on PubMed

Abstract

Gastroparesis is a neuromuscular disorder of the upper gastrointestinal tract. Patients typically complain about early satiety, postprandial fullness, nausea and vomiting. Etiology is multifactorial. Treatment strategies include nutritional support, pharmacologic agents or surgery for refractory cases. Metoclopramide is the first and only FDA approved pharmacologic agent for (diabetic) Gastroparesis. A couple of compounds are currently in clinical testing. Some beacons of hope have failed recently, however. Here we present an update on possible future treatment options.

Address: University Hospital Zürich Switzerland, Department of Gastroenterology and Hepatology, Raemistrasse 100, 8091, Zurich, Switzerland.; University Hospital Zürich Switzerland, Department of Gastroenterology and Hepatology, Raemistrasse 100, 8091, Zurich, Switzerland. Electronic address: [email protected].

DOI: 10.1016/j.coph.2023.102395

Link outs

Free resources

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S1471...

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Gastroparesis, Metoclopramide